Replies to post #236883 on NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

hyperopia,

Think about what Fraunhofer said. They said they improved DCVax-L. My understanding is that in order to do that they had to have done equivalency testing even in process changes to prove that or they would be in trouble for making false claims. They are not only a research hospital but also part of this Phase 3 DCVax-L trial where patients were enrolled. That is why NWBO had to distance themselves (think about Les's reported interpretation) from those "improvement" claims even though equivalency means "essentially the same". So "essentially the same" allows for differences like chemical bond position even though using the same chemical compound just like in generics. Just like original vs generics, though, patients might notice some differences with use hence, perhaps, an explanation for improving 3 year OS outcomes and Fraunhofer's multiple claims. Best wishes.